There are currently 970 clinical trials in Ann Arbor, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Michigan, University of Michigan Comprehensive Cancer Center, University of Michigan Health System and C S Mott Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
NCT06053658
Recruiting
To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Renal Cell Carcinoma
Register for Updates
Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin
NCT06195605
Recruiting
The purpose of the study is to investigate the impact of the injection of dermal filler on the quality of the skin dermal extracellular matrix in persons between the ages of 30-50 years. The quality of the dermal extracellular matrix will be assessed following injection of dermal filler compared to injection of saline vehicle.
Gender:
ALL
Ages:
Between 30 years and 50 years
Trial Updated:
07/02/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Photoaging
Register for Updates
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
NCT06310031
Recruiting
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/02/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Cardiovascular Diseases, Heart Diseases, Heart Failure
Register for Updates
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399
Recruiting
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occu... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/01/2025
Locations: C S Mott Children's Hospital, Ann Arbor, Michigan
Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Register for Updates
WE BEAT - HEART Club Fontan Wellness Project: A Virtual Resilience Promotion and Frailty Prevention Program
NCT05199857
Recruiting
This trial is being conducted to evaluate the effect of a small-group wellness education program combined with a longitudinal, individualized prescription exercise program on the wellness, resiliency, and daily activity levels of pediatric patients with Fontan physiology. There will be two phases for this project. The first phase is the "WE BEAT Group Wellness Education Program" and participants will be transitioned into the phase two HEART Club following phase one. The trial will look at feas... Read More
Gender:
ALL
Ages:
Between 13 years and 18 years
Trial Updated:
07/01/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Fontan Physiology, Frailty, Single Ventricle Heart Disease
Register for Updates
Metastatic Leiomyosarcoma Biomarker Protocol
NCT05653388
Recruiting
Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of metastatic disease. A minority of patients benefit from treatment with chemotherapy and early biomarkers of benefit from treatment are lacking. A biomarker of tumor response and patient survival benefit... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2025
Locations: University of Michigan Cancer Center, Ann Arbor, Michigan
Conditions: Leiomyosarcoma
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Ann Arbor, Michigan
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
NCT04372615
Recruiting
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/30/2025
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Autoimmune Encephalitis, Encephalitis
Register for Updates
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
NCT04471909
Recruiting
Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
Register for Updates
Avapritinib With Decitabine in Patients With SM-AHN
NCT06327685
Recruiting
Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of the disease has the potential to provide enhanced disease control; however, overlapping toxicity is a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Systemic Mastocytosis With an Associated Hematologic Neoplasm
Register for Updates
TENS in Scleroderma
NCT06646913
Recruiting
The goal of this pilot study is to assess the acceptability of the transcutaneous electrical acustimulation (TEA) device in treating Scleroderma-related gastroparesis. The main objective is: To evaluate the acceptability of TEA as an intervention for alleviating symptoms of distension and bloating in individuals diagnosed with Scleroderma. Participants will be provided with the TEA devices that will be applied to the skin for a total of 45 minutes twice daily after meals. Participants will be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Scleroderma, Gastroparesis, Systemic Sclerosis (SSc)
Register for Updates
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Focal Onset Seizures
Register for Updates